Abilify gains expanded bipolar and schizophrenia indications
The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in children 10–17 years of age and for the maintenance treatment of schizophrenia in adolescents 13–17 years of age.
Abilify also gained an indication as an adjunctive therapy to either lithium or valproate for the acute treatment of adults and children ≥10 years of age with manic and mixed episodes associated with bipolar I disorder with or without psychotic features. When used as monotherapy for bipolar I disorder in adults, Abilify now has a lower recommended starting and target dose.
For more information call (800) 321-1335 or visit www.abilify.com.